A small-molecule metallo-immunotherapeutic, Pt-MSA-2-I, created by incorporating DNA damaging cisplatin and a STING agonist into one molecule, can enhance STING activation and remodel the immunosuppressive tumor microenvironment, showing potential against pancreatic cancer. The gene discussed is STING1; the disease is familial pancreatic carcinoma.